Drugs / CD19/CD22 Bispecific CAR-T
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05523661 | Mar 2021 → Mar 2025 | B-lymphoblastic leukemia/lymphoma with t(9;22)(q34.1;q11.2) | Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine | Unknown | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CD19/CD22 Bispecific CAR-T | “To evaluate the safety and efficacy of Dasatinib plus CD19/CD22 Bispecific CAR-T for the treatment of elderly Ph-positive lymphoblastic leukemia.” NCT05523661 ↗ |
| Modality | Cell therapy | “CD19/CD22 Bispecific CAR-T” NCT05523661 ↗ |
| Target | CD19 | “anti-CD19/ CD22 CAR-T cells” NCT05523661 ↗ |
| Target | CD22 | “anti-CD19/ CD22 CAR-T cells” NCT05523661 ↗ |